Rock Creek Group’s TG Therapeutics TGTX Stock Holding History

Rock Creek Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-26,606	Closed	-$308K	–	215
2021 Q4	$308K	Buy	+26,606	New	+$691K	0.05%	112

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Rock Creek Group's TGTX Position: Q1 2022 in Review

Rock Creek Group sold out of TG Therapeutics (TGTX) in Q1 2022, closing a stake of 26,606 shares — an estimated $308K sold.

Rock Creek Group first reported a position in TGTX in Q4 2021 and held it in 1 quarter. The position peaked at $308K in Q4 2021. 181 funds tracked by Wall St. Rank hold TGTX as of Q1 2022.

Rock Creek Group reported no remaining TG Therapeutics position as of Q1 2022 after selling out during the quarter.
Rock Creek Group sold 26,606 TG Therapeutics shares in Q1 2022, an estimated $308K.
Rock Creek Group first reported a position in TG Therapeutics in Q4 2021 and held it in 1 quarter.
Rock Creek Group's TG Therapeutics position peaked at $308K in Q4 2021.
181 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2022.

Based on Rock Creek Group's 13F filing for Q1 2022, filed 11 May 2022.